Bausch Health Companies | VRX - Selling And Administration Expenses


Bausch Health Companies reported $813M in Selling and Administration Expenses for its fiscal quarter ending in March of 2026.





Selling And Administration Expenses Change Date
Amgen USD 1.58B 354M Mar/2026
ANI Pharmaceuticals USD 73.66M 9.14M Mar/2026
Aurora Cannabis CAD 40.62M 1.17M Dec/2025
Bausch Health Companies USD 813M 12M Mar/2026
Biogen USD 554.3M 128.2M Mar/2026
Bristol-Myers Squibb USD 1.62B 564M Mar/2026
Canopy Growth CAD 28.9M 636K Dec/2025
Corcept Therapeutics USD 128.04M 13.3M Mar/2026
Danaher USD 1.86B 166M Mar/2026
Drreddys Laboratories INR 26.92B 3.74B Dec/2025
Eli Lilly USD 2.93B 198M Mar/2026
Gilead Sciences USD 1.45B 326M Mar/2026
Nektar Therapeutics USD 10.17M 10.17M Dec/2025
Novo Nordisk DKK 13.22B 4.22B Mar/2026
Pacira USD 83.88M 7.99M Mar/2026
Perrigo USD 267.3M 11.4M Mar/2026
Phibro Animal Health USD 78.32M 10.24M Dec/2025
Prestige Brands USD 30.28M 606K Mar/2026
Supernus Pharmaceuticals USD 118.23M 4.16M Mar/2026
Vertex Pharmaceuticals USD 493.7M 6.7M Mar/2026
Zoetis USD 588M 31M Mar/2026